A detailed history of Geode Capital Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,289,654 shares of RVNC stock, worth $5.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,289,654
Previous 2,297,965 0.36%
Holding current value
$5.88 Million
Previous $5.91 Million 0.36%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.57 - $2.57 $21,359 - $21,359
-8,311 Reduced 0.36%
2,289,654 $5.88 Million
Q2 2024

Aug 09, 2024

BUY
$2.34 - $4.73 $765,477 - $1.55 Million
327,127 Added 16.6%
2,297,965 $5.91 Million
Q1 2024

May 13, 2024

BUY
$4.65 - $9.31 $215,839 - $432,142
46,417 Added 2.41%
1,970,838 $9.7 Million
Q4 2023

Feb 13, 2024

BUY
$5.81 - $11.2 $837,476 - $1.61 Million
144,144 Added 8.1%
1,924,421 $16.9 Million
Q3 2023

Nov 13, 2023

BUY
$11.47 - $25.07 $972,277 - $2.13 Million
84,767 Added 5.0%
1,780,277 $20.4 Million
Q2 2023

Aug 11, 2023

BUY
$24.7 - $37.61 $2.45 Million - $3.72 Million
98,996 Added 6.2%
1,695,510 $42.9 Million
Q1 2023

May 15, 2023

BUY
$18.36 - $35.27 $1.14 Million - $2.19 Million
62,069 Added 4.05%
1,596,514 $51.4 Million
Q4 2022

Feb 13, 2023

BUY
$18.32 - $30.66 $2.77 Million - $4.64 Million
151,204 Added 10.93%
1,534,445 $28.3 Million
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $2.1 Million - $4.16 Million
146,289 Added 11.83%
1,383,241 $37.3 Million
Q2 2022

Aug 12, 2022

SELL
$11.52 - $20.4 $1.14 Million - $2.02 Million
-99,239 Reduced 7.43%
1,236,952 $17.1 Million
Q1 2022

May 13, 2022

BUY
$12.36 - $20.31 $298,011 - $489,694
24,111 Added 1.84%
1,336,191 $26.1 Million
Q4 2021

Feb 11, 2022

BUY
$12.46 - $27.87 $1.34 Million - $3 Million
107,692 Added 8.94%
1,312,080 $21.4 Million
Q3 2021

Nov 12, 2021

BUY
$25.78 - $33.21 $14,875 - $19,162
577 Added 0.05%
1,204,388 $33.6 Million
Q2 2021

Aug 13, 2021

BUY
$26.8 - $31.84 $2.23 Million - $2.65 Million
83,303 Added 7.43%
1,203,811 $35.7 Million
Q1 2021

May 12, 2021

BUY
$24.03 - $29.97 $3.09 Million - $3.85 Million
128,414 Added 12.94%
1,120,508 $31.3 Million
Q4 2020

Feb 12, 2021

BUY
$23.41 - $28.34 $1.2 Million - $1.46 Million
51,418 Added 5.47%
992,094 $28.1 Million
Q3 2020

Nov 13, 2020

BUY
$23.23 - $34.3 $3.33 Million - $4.91 Million
143,224 Added 17.96%
940,676 $23.6 Million
Q2 2020

Aug 13, 2020

BUY
$12.6 - $26.55 $927,133 - $1.95 Million
73,582 Added 10.17%
797,452 $19.5 Million
Q1 2020

May 14, 2020

BUY
$12.46 - $27.81 $1.7 Million - $3.8 Million
136,718 Added 23.28%
723,870 $10.7 Million
Q4 2019

Feb 13, 2020

BUY
$11.66 - $20.15 $115,387 - $199,404
9,896 Added 1.71%
587,152 $9.53 Million
Q3 2019

Nov 12, 2019

BUY
$10.22 - $14.5 $164,971 - $234,059
16,142 Added 2.88%
577,256 $7.5 Million
Q2 2019

Aug 14, 2019

BUY
$10.67 - $15.49 $776,423 - $1.13 Million
72,767 Added 14.9%
561,114 $7.28 Million
Q1 2019

May 14, 2019

BUY
$15.4 - $20.39 $1.58 Million - $2.09 Million
102,529 Added 26.57%
488,347 $7.7 Million
Q4 2018

Feb 13, 2019

BUY
$18.06 - $24.96 $872,749 - $1.21 Million
48,325 Added 14.32%
385,818 $7.77 Million
Q3 2018

Nov 13, 2018

BUY
$23.55 - $30.1 $786,664 - $1.01 Million
33,404 Added 10.98%
337,493 $8.39 Million
Q2 2018

Aug 14, 2018

BUY
$27.45 - $33.35 $1.14 Million - $1.39 Million
41,697 Added 15.89%
304,089 $8.35 Million
Q1 2018

May 15, 2018

BUY
$29.15 - $37.4 $1.25 Million - $1.6 Million
42,831 Added 19.51%
262,392 $8.08 Million
Q4 2017

Feb 13, 2018

BUY
$24.55 - $36.3 $406,081 - $600,438
16,541 Added 8.15%
219,561 $7.85 Million
Q3 2017

Nov 14, 2017

BUY
$22.55 - $28.1 $250,958 - $312,724
11,129 Added 5.8%
203,020 $5.59 Million
Q2 2017

Aug 14, 2017

BUY
N/A
191,891
191,891 $5.07 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.